The role of p53 in limiting somatic cell reprogramming

Cell Res. 2009 Nov;19(11):1227-8. doi: 10.1038/cr.2009.121. Epub 2009 Nov 2.

Authors

Yan Liu¹, Ruben Hoya-Arias, Stephen D Nimer

Affiliation

¹ Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

PMID: 19881523
DOI: 10.1038/cr.2009.121

No abstract available

MeSH terms

Animals
Apoptosis / genetics
Cell Cycle / genetics
Cell Transformation, Neoplastic
Cellular Reprogramming*
Cyclin-Dependent Kinase Inhibitor p16 / antagonists & inhibitors
Cyclin-Dependent Kinase Inhibitor p16 / genetics
Cyclin-Dependent Kinase Inhibitor p16 / metabolism
Cyclin-Dependent Kinase Inhibitor p21 / genetics
Cyclin-Dependent Kinase Inhibitor p21 / metabolism
Fibroblasts / physiology
Gene Expression Regulation*
Genomic Instability
Hematopoietic Stem Cells / physiology
Humans
Induced Pluripotent Stem Cells* / metabolism
Induced Pluripotent Stem Cells* / pathology
Mice
Mutagenesis, Insertional
Proto-Oncogene Proteins c-mdm2 / genetics
Proto-Oncogene Proteins c-mdm2 / metabolism
Tumor Suppressor Protein p53 / antagonists & inhibitors
Tumor Suppressor Protein p53 / genetics*
Tumor Suppressor Protein p53 / metabolism*

Substances

CDKN1A protein, human
Cdkn2a protein, mouse
Cyclin-Dependent Kinase Inhibitor p16
Cyclin-Dependent Kinase Inhibitor p21
Tumor Suppressor Protein p53
MDM2 protein, human
Proto-Oncogene Proteins c-mdm2